FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2473280931> ?p ?o ?g. }

• W2473280931 endingPage "1300" @default.
• W2473280931 startingPage "1295" @default.
• W2473280931 abstract "Sorafenib is the only therapy shown to improve overall survival in advanced hepatocellular carcinoma (HCC). However, the clinical efficacy of sorafenib is limited. Combination therapy targeting multiple signaling pathways may improve outcomes. Ginkgo biloba extract (GBE) has exhibited antitumor activity in multiple human cancers. This study was designed to evaluate the tolerability and effectiveness of GBE combined with sorafenib in patients with advanced HCC. Patients with advanced HCC were treated with increasing doses of GBE in combination with sorafenib. We first determined the maximum tolerated dose (MTD) of GBE, then the patients were treated with GBE at the MTD to evaluate its safety and efficacy. 27 patients were enrolled in the first part of our study and treated with sorafenib 400 mg twice daily (BID) and increasing doses (cohort 1: 60 mg, cohort 2: 120 mg, cohort 3: 240 mg, cohort 4: 360 mg) of GBE once daily (QD). An additional group of 32 new patients next to the 27 described before were accrued for the second part of our study, and all these 32 patients were eligible for the evaluation of toxicity and efficacy. No patient in cohort 1 and 2 experienced a dose-limiting toxicity (DLT). One of the ten patients in cohort 3 experienced a DLT. DLT occurred in two of the three initial patients in cohort 4. Cohort 3 (GBE 240 mg QD plus sorafenib 400 mg BID) was considered to be the MTD. Three patients had a partial response, 21 had stable disease, and 8 had progressive disease. The median times to progression and overall survival were 2.5 and 11.6 months, respectively. Compared with previous study, the toxicities of the combination therapy were similar with those observed in sorafenib monotherapy, GBE in combination with sorafenib slightly improved OS. The combination of GBE (240 mg QD) and standard dose sorafenib (400 mg BID) is safe and tolerable among patients with advanced HCC. Early signs of antitumor activity may warrant further development of this combination." @default.
• W2473280931 created "2016-07-22" @default.
• W2473280931 creator A5000709108 @default.
• W2473280931 creator A5028062947 @default.
• W2473280931 creator A5040035306 @default.
• W2473280931 creator A5052861559 @default.
• W2473280931 creator A5082972798 @default.
• W2473280931 creator A5089639451 @default.
• W2473280931 date "2016-11-01" @default.
• W2473280931 modified "2023-10-16" @default.
• W2473280931 title "Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients" @default.
• W2473280931 cites W1970060716 @default.
• W2473280931 cites W1971837077 @default.
• W2473280931 cites W1981989535 @default.
• W2473280931 cites W1985960080 @default.
• W2473280931 cites W1990630860 @default.
• W2473280931 cites W1994193851 @default.
• W2473280931 cites W1998601811 @default.
• W2473280931 cites W2001856011 @default.
• W2473280931 cites W2004274458 @default.
• W2473280931 cites W2009378668 @default.
• W2473280931 cites W2017107262 @default.
• W2473280931 cites W2019691599 @default.
• W2473280931 cites W2074433596 @default.
• W2473280931 cites W2095132575 @default.
• W2473280931 cites W2098141984 @default.
• W2473280931 cites W2103372520 @default.
• W2473280931 cites W2111174450 @default.
• W2473280931 cites W2139025268 @default.
• W2473280931 cites W2140765540 @default.
• W2473280931 cites W2153283736 @default.
• W2473280931 cites W2153935627 @default.
• W2473280931 cites W2157262448 @default.
• W2473280931 cites W2163403599 @default.
• W2473280931 cites W2211968863 @default.
• W2473280931 doi "https://doi.org/10.1016/j.phymed.2016.07.002" @default.
• W2473280931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27765348" @default.
• W2473280931 hasPublicationYear "2016" @default.
• W2473280931 type Work @default.
• W2473280931 sameAs 2473280931 @default.
• W2473280931 citedByCount "11" @default.
• W2473280931 countsByYear W24732809312017 @default.
• W2473280931 countsByYear W24732809312018 @default.
• W2473280931 countsByYear W24732809312021 @default.
• W2473280931 countsByYear W24732809312022 @default.
• W2473280931 countsByYear W24732809312023 @default.
• W2473280931 crossrefType "journal-article" @default.
• W2473280931 hasAuthorship W2473280931A5000709108 @default.
• W2473280931 hasAuthorship W2473280931A5028062947 @default.
• W2473280931 hasAuthorship W2473280931A5040035306 @default.
• W2473280931 hasAuthorship W2473280931A5052861559 @default.
• W2473280931 hasAuthorship W2473280931A5082972798 @default.
• W2473280931 hasAuthorship W2473280931A5089639451 @default.
• W2473280931 hasConcept C126322002 @default.
• W2473280931 hasConcept C141071460 @default.
• W2473280931 hasConcept C143998085 @default.
• W2473280931 hasConcept C197934379 @default.
• W2473280931 hasConcept C2776694085 @default.
• W2473280931 hasConcept C2776999253 @default.
• W2473280931 hasConcept C2778019345 @default.
• W2473280931 hasConcept C2778375690 @default.
• W2473280931 hasConcept C2778695046 @default.
• W2473280931 hasConcept C2778822529 @default.
• W2473280931 hasConcept C71924100 @default.
• W2473280931 hasConcept C72563966 @default.
• W2473280931 hasConcept C90924648 @default.
• W2473280931 hasConcept C98274493 @default.
• W2473280931 hasConceptScore W2473280931C126322002 @default.
• W2473280931 hasConceptScore W2473280931C141071460 @default.
• W2473280931 hasConceptScore W2473280931C143998085 @default.
• W2473280931 hasConceptScore W2473280931C197934379 @default.
• W2473280931 hasConceptScore W2473280931C2776694085 @default.
• W2473280931 hasConceptScore W2473280931C2776999253 @default.
• W2473280931 hasConceptScore W2473280931C2778019345 @default.
• W2473280931 hasConceptScore W2473280931C2778375690 @default.
• W2473280931 hasConceptScore W2473280931C2778695046 @default.
• W2473280931 hasConceptScore W2473280931C2778822529 @default.
• W2473280931 hasConceptScore W2473280931C71924100 @default.
• W2473280931 hasConceptScore W2473280931C72563966 @default.
• W2473280931 hasConceptScore W2473280931C90924648 @default.
• W2473280931 hasConceptScore W2473280931C98274493 @default.
• W2473280931 hasIssue "12" @default.
• W2473280931 hasLocation W24732809311 @default.
• W2473280931 hasLocation W24732809312 @default.
• W2473280931 hasOpenAccess W2473280931 @default.
• W2473280931 hasPrimaryLocation W24732809311 @default.
• W2473280931 hasRelatedWork W1995934654 @default.
• W2473280931 hasRelatedWork W2118887459 @default.
• W2473280931 hasRelatedWork W2272794294 @default.
• W2473280931 hasRelatedWork W2314455959 @default.
• W2473280931 hasRelatedWork W2322773431 @default.
• W2473280931 hasRelatedWork W2370121646 @default.
• W2473280931 hasRelatedWork W2381257096 @default.
• W2473280931 hasRelatedWork W2392900588 @default.
• W2473280931 hasRelatedWork W2466156289 @default.
• W2473280931 hasRelatedWork W3030875434 @default.
• W2473280931 hasVolume "23" @default.
• W2473280931 isParatext "false" @default.

• next